Advertisement

Differential regulation of C-type natriuretic peptide-induced cGMP and functional responses by PDE2 and PDE3 in failing myocardium

  • Lise Román Moltzau
  • Silja Meier
  • Jan Magnus Aronsen
  • Faraz Afzal
  • Ivar Sjaastad
  • Tor Skomedal
  • Jan-Bjørn Osnes
  • Finn Olav LevyEmail author
  • Eirik Qvigstad
Original Article

Abstract

Recently, we showed C-type natriuretic peptide (CNP)-induced negative inotropic (NIR) and positive lusitropic response (LR) in failing rat heart. We wanted to study whether, and if so, how phosphodiesterases (PDEs) regulate CNP-induced cyclic 3′,5′-guanosine monophosphate (cGMP) elevation and functional responses. Inotropic and lusitropic responses were measured in left ventricular muscle strips and cyclic nucleotide levels, PDE activity and phospholamban (PLB) and troponin I (TnI) phosphorylation were measured in ventricular cardiomyocytes from Wistar rats with heart failure 6 weeks after myocardial infarction. CNP-mediated increase in global cGMP was mainly regulated by PDE2, as reflected by a marked amplification of the cGMP increase during PDE2 inhibition and by a high PDE2 activity in cardiomyocytes. PDE3 inhibition, on the other hand, caused no significant cGMP increase by CNP. The functional consequences did not correspond to the changes of cGMP. PDE3 inhibition increased the potency of the CNP-induced NIR and LR, while PDE2 inhibition desensitized the CNP-induced NIR, but not LR. A role for PDE2 on the maximal LR and PDE5 on the maximal NIR to CNP was revealed in the presence of PDE3 inhibition. CNP increased PLB phosphorylation about 25- to 30-fold and tended to increase TnI phosphorylation about twofold. As a whole, CNP-induced functional responses were only modestly regulated by PDEs compared to the cAMP-mediated functional responses to β1-adrenoceptor stimulation, which are highly regulated by PDEs. There is a mismatch between the CNP-induced cGMP increase and functional responses. Global cGMP levels are mainly regulated by PDE2 after CNP stimulation, whereas the functional responses are modestly regulated by both PDE2 and PDE3, indicating cGMP compartmentation by PDEs affecting CNP-induced responses in failing hearts.

Keywords

CNP cGMP Heart failure Phosphodiesterase Negative inotropic response Lusitropic response 

Notes

Acknowledgments

We would like to thank Iwona Gutowska Schiander for isolation of cardiomyocytes and Cam HT Nguyen and Marie Dahl for performing Western blot experiments. This work was supported by The Norwegian Council on Cardiovascular Disease, The Research Council of Norway, Stiftelsen Kristian Gerhard Jebsen, Anders Jahre’s Foundation for the Promotion of Science, The Family Blix Foundation, The Simon Fougner Hartmann Foundation, South-Eastern Norway Regional Health Authority, University of Oslo and the COST Action BM1005 (European Network on Gasotransmitters).

Supplementary material

210_2013_953_MOESM1_ESM.doc (63 kb)
Online Resource (DOC 63 kb)

References

  1. Afzal F, Andressen KW, Mørk HK, Aronsen JM, Sjaastad I, Dahl CP, Skomedal T, Levy FO, Osnes JB, Qvigstad E (2008) 5-HT4-elicited positive inotropic response is mediated by cAMP and regulated by PDE3 in failing rat and human cardiac ventricles. Br J Pharmacol 155:1005–1014PubMedCentralPubMedCrossRefGoogle Scholar
  2. Afzal F, Aronsen JM, Moltzau LR, Sjaastad I, Levy FO, Skomedal T, Osnes JB, Qvigstad E (2011a) Differential regulation of β2-adrenoceptor-mediated inotropic and lusitropic response by PDE3 and PDE4 in failing and non-failing rat cardiac ventricle. Br J Pharmacol 162:54–71Google Scholar
  3. Afzal F, Qvigstad E, Aronsen JM, Moltzau LR, Sjaastad I, Skomedal T, Osnes JB, Levy FO (2011b) Agents increasing cyclic GMP amplify 5-HT(4)-elicited positive inotropic response in failing rat cardiac ventricle. Naunyn Schmiedebergs Arch Pharmacol 384(6):543–553PubMedCentralPubMedCrossRefGoogle Scholar
  4. Anand-Srivastava MB, Cantin M (1986) Atrial natriuretic factor receptors are negatively coupled to adenylate cyclase in cultured atrial and ventricular cardiocytes. Biochem Biophys Res Commun 138:427–436PubMedCrossRefGoogle Scholar
  5. Anand-Srivastava MB, Sairam MR, Cantin M (1990) Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system. J Biol Chem 265:8566–8572PubMedGoogle Scholar
  6. Birkeland JA, Sjaastad I, Brattelid T, Qvigstad E, Moberg ER, Krobert KA, Bjørnerheim R, Skomedal T, Sejersted OM, Osnes JB, Levy FO (2007) Effects of treatment with a 5-HT4 receptor antagonist in heart failure. Br J Pharmacol 150:143–152PubMedCentralPubMedCrossRefGoogle Scholar
  7. Boerrigter G, Lapp H, Burnett JC (2009) Modulation of cGMP in heart failure: a new therapeutic paradigm. In: Schmidt HHHW, Hofmann F, Stasch JP (eds) Handbook of experimental pharmacology. Springer, Heidelberg, pp 485–506Google Scholar
  8. Castro LR, Verde I, Cooper DM, Fischmeister R (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113:2221–2228PubMedCentralPubMedCrossRefGoogle Scholar
  9. Del Ry S, Passino C, Maltinti M, Emdin M, Giannessi D (2005) C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 7:1145–1148PubMedCrossRefGoogle Scholar
  10. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR (2007) Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 148:3518–3522PubMedCrossRefGoogle Scholar
  11. Doyle DD, Upshaw-Earley J, Bell EL, Palfrey HC (2002) Natriuretic peptide receptor-B in adult rat ventricle is predominantly confined to the nonmyocyte population. Am J Physiol Heart Circ Physiol 282:H2117–H2123PubMedGoogle Scholar
  12. Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91:651–690PubMedCrossRefGoogle Scholar
  13. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, Coats AJ (2003) Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 107:571–573PubMedCrossRefGoogle Scholar
  14. Kauffman RF, Crowe VG, Utterback BG, Robertson DW (1986) LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol 30:609–616PubMedGoogle Scholar
  15. Levy FO (2013) Cardiac PDEs and crosstalk between cAMP and cGMP signalling pathways in the regulation of contractility. Naunyn Schmiedebergs Arch Pharmacol 386:665–670PubMedCrossRefGoogle Scholar
  16. Lugnier C, Muller B, Le BA, Beaudry C, Rousseau E (1993) Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions. J Pharmacol Exp Ther 265:1142–1151PubMedGoogle Scholar
  17. Marchmont RJ, Houslay MD (1980) A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J 187:381–392PubMedCentralPubMedGoogle Scholar
  18. Mehel H, Emons J, Vettel C, Wittkopper K, Seppelt D, Dewenter M et al (2013) Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes. J Am Coll Cardiol 62:1596–1606Google Scholar
  19. Mery PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R (1993) Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268:26286–26295PubMedGoogle Scholar
  20. Mika D, Leroy J, Vandecasteele G, Fischmeister R (2012) PDEs create local domains of cAMP signaling. J Mol Cell Cardiol 52:323–329PubMedCrossRefGoogle Scholar
  21. Moltzau LR, Aronsen JM, Meier S, Nguyen CH, Hougen K, Ørstavik Ø, Sjaastad I, Christensen G, Skomedal T, Osnes JB, Levy FO, Qvigstad E (2013) SERCA2 activity is involved in the CNP-mediated functional responses in failing rat myocardium. Br J Pharmacol 170:366–379Google Scholar
  22. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M (2006) Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res 98:226–234PubMedCrossRefGoogle Scholar
  23. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V et al (2011) Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32–43PubMedCrossRefGoogle Scholar
  24. Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309–327PubMedCrossRefGoogle Scholar
  25. Potter LR, Yoder AR, Flora DR, Antos LK, Dickey DM (2009) Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. In: Schmidt HHHW, Hofmann F, Stasch JP (eds) Handbook of experimental pharmacology. Springer, Heidelberg, pp 341–366Google Scholar
  26. Qvigstad E, Moltzau LR, Aronsen JM, Nguyen CH, Hougen K, Sjaastad I, Levy FO, Skomedal T, Osnes JB (2010) Natriuretic peptides increase β1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 85:763–772Google Scholar
  27. Rose RA, Lomax AE, Giles WR (2003) Inhibition of L-type Ca2+ current by C-type natriuretic peptide in bullfrog atrial myocytes: an NPR-C-mediated effect. Am J Physiol Heart Circ Physiol 285:H2454–H2462PubMedGoogle Scholar
  28. Sjaastad I, Sejersted OM, Ilebekk A, Bjørnerheim R (2000) Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. J Appl Physiol 89:1445–1454PubMedGoogle Scholar
  29. Sjaastad I, Schiander I, Sjetnan A, Qvigstad E, Bøkenes J, Sandnes D, Osnes JB, Sejersted OM, Skomedal T (2003) Increased contribution of alpha1- vs. beta-adrenoceptor-mediated inotropic response in rats with congestive heart failure. Acta Physiol Scand 177:449–458PubMedCrossRefGoogle Scholar
  30. Skomedal T, Grynne B, Osnes JB, Sjetnan AE, Øye I (1980) A radioimmunoassay for cyclic AMP (cAMP) obtained by acetylation of both unlabeled and labeled (3H-cAMP) ligand, or of unlabeled ligand only. Acta Pharmacol Toxicol (Copenh) 46:200–204CrossRefGoogle Scholar
  31. Skomedal T, Borthne K, Aass H, Geiran O, Osnes JB (1997) Comparison between alpha-1 adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 280:721–729PubMedGoogle Scholar
  32. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, Berrera M, Surdo NC, Craig MA, Smith G, Hamilton G, Zaccolo M (2011) cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ Res 108:929–939PubMedCentralPubMedCrossRefGoogle Scholar
  33. Su J, Scholz PM, Weiss HR (2005) Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood) 230:242–250Google Scholar
  34. Vandeput F, Krall J, Ockaili R, Salloum FN, Florio V, Corbin JD, Francis SH, Kukreja RC, Movsesian MA (2009) cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther 330:884–891PubMedCentralPubMedCrossRefGoogle Scholar
  35. Weninger S, De Maeyer JH, Lefebvre RA (2012) Study of the regulation of the inotropic response to 5-HT4 receptor activation via phosphodiesterases and its cross-talk with C-type natriuretic peptide in porcine left atrium. Naunyn Schmiedebergs Arch Pharmacol 385:565–577PubMedCrossRefGoogle Scholar
  36. Weninger S, De Maeyer JH, Lefebvre RA (2013) Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium. Naunyn Schmiedebergs Arch Pharmacol 386:671–684PubMedCrossRefGoogle Scholar
  37. Zaccolo M, Movsesian MA (2007) cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 100:1569–1578PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Lise Román Moltzau
    • 1
    • 2
  • Silja Meier
    • 1
    • 2
  • Jan Magnus Aronsen
    • 2
    • 3
    • 4
  • Faraz Afzal
    • 1
    • 2
  • Ivar Sjaastad
    • 2
    • 3
  • Tor Skomedal
    • 1
    • 2
  • Jan-Bjørn Osnes
    • 1
    • 2
  • Finn Olav Levy
    • 1
    • 2
    Email author
  • Eirik Qvigstad
    • 1
    • 2
  1. 1.Department of Pharmacology, Institute of Clinical MedicineUniversity of Oslo and Oslo University HospitalOsloNorway
  2. 2.K.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research, Faculty of MedicineUniversity of OsloOsloNorway
  3. 3.Institute for Experimental Medical Research, Institute of Clinical MedicineUniversity of Oslo and Oslo University HospitalOsloNorway
  4. 4.Bjørknes CollegeOsloNorway

Personalised recommendations